In an interview with News Medical, Dr. Bryony Henderson, Medical Director for the UK and US at MedExpress, discussed the growing role of GLP-1 agonists in obesity treatment and their broader impact on metabolic health.
Dr. Henderson leads clinical governance and quality teams at MedExpress, focusing on patient safety as digital healthcare evolves. Her previous experience includes leadership roles in clinical operations and digital health at Kry/Livi and Numan, as well as involvement in public health campaigns and research on health inequalities.
GLP-1 receptor agonists work by mimicking a hormone produced in the gut after eating. According to Dr. Henderson, these medications act as a "biological bridge" by stimulating insulin release from the pancreas, slowing gastric emptying to increase satiety, and reducing cravings by interacting with brain reward centers. She emphasized that understanding these drugs as hormonal interventions rather than simple appetite suppressants helps patients see them as tools to reset metabolic signals.
Currently, GLP-1 injections are prescribed mainly for adults with obesity (BMI over 30), or those with BMI over 27 who have additional weight-related conditions such as high blood pressure or prediabetes. Dr. Henderson noted that clinical supervision is essential, especially as the range of potential benefits expands beyond weight loss alone.
Looking ahead to 2026, she expects GLP-1s will be used for more indications including osteoarthritis, cardiovascular disease, chronic kidney disease, sleep apnea, and some neurodegenerative disorders. "We are moving from 'weight loss drugs' to 'metabolic health stabilisers,'" she said.
Dr. Henderson stressed that long-term success depends on comprehensive care: "Sustainability is highly dependent on the 'wraparound' care provided." She anticipates more personalized dosing schedules and tracking tools will help patients maintain improvements even if they stop medication.
Addressing misconceptions about GLP-1s being quick fixes or "vanity drugs," Dr. Henderson said psychological support should be considered essential alongside medication to address behavioral relationships with food: "The most successful treatment models in 2026 will be those that combine medication with behavioral change."
Access remains limited through public systems like the NHS compared to demand. Private prescribing offers earlier access but creates a two-tier system. However, she expects 2026 will bring greater equity globally due to generic versions entering markets after patent expirations for semaglutide and liraglutide.
Dr. Henderson also called for more flexible guidelines tailored to individual needs while maintaining clinical oversight: "We need to ensure that widening access... does not come at the expense of clinical oversight."
She observed that GLP-1s are changing perceptions about obesity by highlighting hormonal influences rather than framing it solely as a matter of lifestyle choices or willpower: "They are helping dismantle the ‘willpower myth.’"
Over the next decade, Dr. Henderson predicts GLP-1s will anchor a holistic approach combining new therapies—including oral formulations like orforglipron—with technology such as wearable devices for real-time monitoring and personalized nutritional coaching.
More information about MedExpress can be found at https://www.medexpress.co.uk/.
Dr. Bryony Henderson recently joined HeliosX as Medical Director for the UK and US where she oversees clinical governance and quality initiatives supporting safe and innovative care delivery based on her extensive background in digital health leadership roles.
